UCB (OTCMKTS:UCBJF) Sees Large Volume Increase – Time to Buy?

UCB SA (OTCMKTS:UCBJF – Get Free Report) shares saw unusually-high trading volume on Thursday . Approximately 2,448 shares traded hands during trading, an increase of 213% from the previous session’s volume of 781 shares.The stock last traded at $286.7250 and had previously closed at $289.84.

Analyst Upgrades and Downgrades

UCBJF has been the subject of a number of research analyst reports. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a report on Monday, February 16th. Wolfe Research assumed coverage on UCB in a report on Monday, February 23rd. They set an “outperform” rating for the company. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, UCB currently has a consensus rating of “Buy”.

Get UCB alerts:

View Our Latest Research Report on UCB

UCB Stock Down 1.1%

The firm has a 50 day simple moving average of $295.05 and a 200-day simple moving average of $296.37. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

(Get Free Report)

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.

Further Reading

• Five stocks we like better than UCB
• RTX Is Set to Revolutionize Munitions Manufacturing
• Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It
• Is Co-Diagnostics National Security’s Next Diagnostic Pick?
• If the Market Rally Stalls, This ETF Can Insulate Portfolios

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.